{
  "ticker": "BXN",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972198",
  "id": "02972198",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250724",
  "time": "0909",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m2zs953bkny6.pdf",
  "summary": "### **Key Material Information (Q4 Activities Report & Appendix 4C)**  \n\n#### **Operational & Financial Highlights**  \n- **Record quarterly revenue**: **$9.5M** (+204% YoY, +33% QoQ).  \n- **FY25 unaudited revenue**: **$29.3M** (exceeding guidance of **$28M** by **$1.3M**).  \n- **Cash receipts**: **$10.7M** (+302% YoY, +26% QoQ).  \n- **Positive operating cash flow**: **$1.5M** (4th consecutive quarter).  \n- **Cash balance**: **$7.6M** (end of quarter).  \n\n#### **Strategic Developments**  \n- **German market entry**: **\u20ac3.2M (A$5.8M)** manufacturing/supply agreement (Farmakem & Adrex).  \n- **Expansion focus**: EU/UK growth, with EU GMP certification in Czechia targeted.  \n\n#### **Appendix 4C Summary**  \n- **Net operating cash flow (12 months)**: **$6.2M**.  \n- **Capex (quarter)**: **$0.3M** (full-year **$2.4M**).  \n- **No debt facilities drawn**.  \n\n#### **Outlook**  \n- FY26 guidance to be provided with FY25 results. Focus on scaling EU/UK operations.  \n\n**No material capital raising, M&A, or trading halt details identified.**",
  "usage": {
    "prompt_tokens": 4866,
    "completion_tokens": 323,
    "total_tokens": 5189,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T23:16:02.588685"
}